REFERENCES


3 Perlitz U., 2008, India’s pharmaceutical industry on course for globalisation, dbresearch Frankfurt, pp-1-12


7 Davit B et al., (2009), Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration, The Annals of Pharmacotherapy, vol. 43, 10, pp 1583-1597


12 Matuszewski B. et al., 2003, Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MS, analytical chemistry, 75 (13), pp 3019–3030


16 W Naidong, et al., 2007, Recent advances in high-throughput quantitative bioanalysis by LC−MS/MS, Journal of Pharmaceutical and Biomedical Analysis, 44( 2), Pages 342–355


19 Górecki T., et al., 1999, Theory of analyte extraction by selected porous polymer SPME fibres, Analyst, 124, pp 643-649

REFERENCES


22 Colin F. Poole, 2002, Chapter 12 Principles and practice of solid-phase extraction, Comprehensive Analytical Chemistry, Volume 37, Pages 341–387


24 Frank D , Pat S, 2007, Stir bar sorptive extraction for trace analysis, Journal of Chromatography A, Volume 1152, Issues 1–2, 8 June 2007, Pages 54–69


REFERENCES


32 Ackermann L., Berna J, Murphy T., 2002, Recent Advances in use of LC/MS/MS for Quantitative High-Throughput Bioanalytical Support of Drug Discovery, Current Topics in Medicinal Chemistry, Volume 2, Number 1, pp. 53-66(14)

33 Maurer H., 2006, Hyphenated mass spectrometric techniques – indispensable tools in clinical and forensic toxicology and in doping control, Journal of Mass spectrometry, 41, 1399–1413


39 Technical Brief 2009, Particle Sciences, drug development services, Volume 4,1-2


55 Strack T., 2008, Metformin: a review, Drugs Today (Barc), 44(4):303-14
58 Bernstein CD, Albrecht KL, Marcus DA., 2013, Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium, Expert Opin Pharmacother, 14(7):905-16.
64 Berg J, Fellier H, Christoph T, Grarup J, Stimmender D, 1999, The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS) and the formation of interleukin (IL)-6 in vitro, Inflammation Research 48(7), 369-379.


Fujita, T., Takamatsu, T., Hisamoto, T., Tsutsumi, J., Kinoshita, K., and Kanai, T. (1981), Studies on the metabolic fate of 4’-ethyl-2- methyl-3-


86 http://multiple-sclerosis.emedtv.com/gilenya/generic-gilenya

87 Zollinger M et al., 2011, Absorption and Disposition of the Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) in Healthy Volunteers: A Case of Xenobiotic Biotransformation Following Endogenous Metabolic Pathways Drug Metab Dispos 39:199-207


91 LK Golightly , CC Drayna , MT McDermott , 2012, Comparative clinical pharmacoki-netics of dipeptidyl peptidase-4 inhibitors, Clin Pharmacokinet. 1;51(8):501-14


Yan-Ling He, Ron Sabo, Franck Picard, Yibin Wang, Jerry Herron, Monica Ligueros-Saylan, and William P. Dole, May 2009, Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes, Current Medical Research and Opinion, Vol. 25, No. 5 : Pages 1265-1272


Zecrubier Y. Milnacipran: The clinical properties of a selective serotonin and noradrenaline reuptake inhibitor (SNRI), Human psychopharmacology, 1997, 12, S127-S34.


REFERENCES


114  www.fda.gov

115  www.rxlist.com

116  chembank.broadinstitute.org/